CD24 and hematologic disorder: In this regard, the overexpression of CD24 has been documented in several malignancies, including breast [29,30], lung [31], colorectal [32], hepatocellular [27], pancreatic [33], ovarian [30], urothelial [34], prostate [35], and head and neck cancer [36], as well as in primary central nervous system (CNS) tumors [37,38] and hematologic malignancies [39,40,41] (Table 1).